• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

益生菌:塑造肠道免疫反应。

Probiotics: Shaping the gut immunological responses.

机构信息

Faculty of Medicine, Laboratory of Pharmacology, Democritus University of Thrace, Alexandroupolis 68100, Greece.

Department of Surgery, Aristotle University of Thessaloniki, Thessaloniki 54636, Greece.

出版信息

World J Gastroenterol. 2024 Apr 21;30(15):2096-2108. doi: 10.3748/wjg.v30.i15.2096.

DOI:10.3748/wjg.v30.i15.2096
PMID:38681982
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11045475/
Abstract

Probiotics are live microorganisms exerting beneficial effects on the host's health when administered in adequate amounts. Among the most popular and adequately studied probiotics are bacteria from the families , and yeasts. Most of them have been shown, both and studies of intestinal inflammation models, to provide favorable results by means of improving the gut microbiota composition, promoting the wound healing process and shaping the immunological responses. Chronic intestinal conditions, such as inflammatory bowel diseases (IBD), are characterized by an imbalance in microbiota composition, with decreased diversity, and by relapsing and persisting inflammation, which may lead to mucosal damage. Although the results of the clinical studies investigating the effect of probiotics on patients with IBD are still controversial, it is without doubt that these microorganisms and their metabolites, now named postbiotics, have a positive influence on both the host's microbiota and the immune system, and ultimately alter the topical tissue microenvironment. This influence is achieved through three axes: (1) By displacement of potential pathogens competitive exclusion; (2) by offering protection to the host through the secretion of various defensive mediators; and (3) by supplying the host with essential nutrients. We will analyze and discuss almost all the and studies of the past 2 years dealing with the possible favorable effects of certain probiotic genus on gut immunological responses, highlighting which species are the most beneficial against intestinal inflammation.

摘要

益生菌是指当给予足够量时,对宿主健康产生有益影响的活微生物。在最受欢迎和研究充分的益生菌中,有来自 和 科的细菌以及酵母。大多数益生菌已经被证明,无论是在肠道炎症模型的体内研究还是体外研究中,都可以通过改善肠道微生物群落组成、促进伤口愈合过程和塑造免疫反应来提供有利的结果。慢性肠道疾病,如炎症性肠病(IBD),其特征是微生物群落组成失衡,多样性降低,炎症反复发作和持续存在,可能导致黏膜损伤。尽管关于益生菌对 IBD 患者影响的临床研究结果仍存在争议,但毫无疑问,这些微生物及其代谢产物,现在称为后生元,对宿主的微生物群和免疫系统都有积极影响,并最终改变局部组织微环境。这种影响是通过三个轴实现的:(1)通过潜在病原体的取代来实现 竞争排除;(2)通过分泌各种防御介质来为宿主提供保护;(3)通过为宿主提供必需的营养物质。我们将分析和讨论过去 2 年中几乎所有涉及某些益生菌属对肠道免疫反应可能有益影响的体内和体外研究,突出哪些物种对肠道炎症最有益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c67/11045475/6f6b71a5cf89/WJG-30-2096-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c67/11045475/6f6b71a5cf89/WJG-30-2096-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c67/11045475/6f6b71a5cf89/WJG-30-2096-g001.jpg

相似文献

1
Probiotics: Shaping the gut immunological responses.益生菌:塑造肠道免疫反应。
World J Gastroenterol. 2024 Apr 21;30(15):2096-2108. doi: 10.3748/wjg.v30.i15.2096.
2
The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.炎症、营养供应和共生微生物群在肠道病原体感染中的作用。
Microbiol Spectr. 2015 Jun;3(3). doi: 10.1128/microbiolspec.MBP-0008-2014.
3
Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics.益生菌对肠道、肠道炎性疾病及肝脏中免疫和炎性基因表达的调节作用。
World J Gastroenterol. 2014 Nov 14;20(42):15632-49. doi: 10.3748/wjg.v20.i42.15632.
4
Microbes, intestinal inflammation and probiotics.微生物、肠道炎症与益生菌。
Expert Rev Gastroenterol Hepatol. 2012 Feb;6(1):81-94. doi: 10.1586/egh.11.94.
5
Anti-Inflammatory and Immunomodulatory Effects of Probiotics in Gut Inflammation: A Door to the Body.益生菌在肠道炎症中的抗炎和免疫调节作用:通往身体的一扇门。
Front Immunol. 2021 Feb 26;12:578386. doi: 10.3389/fimmu.2021.578386. eCollection 2021.
6
Links Between Inflammatory Bowel Disease and Chronic Obstructive Pulmonary Disease.炎症性肠病与慢性阻塞性肺疾病的关联。
Front Immunol. 2020 Sep 11;11:2144. doi: 10.3389/fimmu.2020.02144. eCollection 2020.
7
The role of the microbiome in gastrointestinal inflammation.微生物组在胃肠道炎症中的作用。
Biosci Rep. 2021 Jun 25;41(6). doi: 10.1042/BSR20203850.
8
Probiotics in Intestinal Mucosal Healing: A New Therapy or an Old Friend?益生菌与肠道黏膜愈合:一种新疗法还是老朋友?
Pharmaceuticals (Basel). 2021 Nov 19;14(11):1181. doi: 10.3390/ph14111181.
9
Postbiotics: An alternative and innovative intervention for the therapy of inflammatory bowel disease.后生元:炎症性肠病治疗的一种替代和创新干预措施。
Microbiol Res. 2024 Feb;279:127550. doi: 10.1016/j.micres.2023.127550. Epub 2023 Nov 19.
10
Recent progress on the role of gut microbiota in the pathogenesis of inflammatory bowel disease.肠道微生物群在炎症性肠病发病机制中的作用的最新进展。
J Dig Dis. 2013 Oct;14(10):513-7. doi: 10.1111/1751-2980.12087.

引用本文的文献

1
Lithocholic acid ameliorates ulcerative colitis via the PXR/TLR4/NF-κB/NLRP3 signaling pathway and gut microbiota modulation.石胆酸通过PXR/TLR4/NF-κB/NLRP3信号通路和肠道微生物群调节改善溃疡性结肠炎。
Cell Mol Life Sci. 2025 Sep 4;82(1):336. doi: 10.1007/s00018-025-05834-2.
2
and alleviate enterotoxigenic -induced intestinal inflammation and stabilize intestinal microorganisms and serum metabolites in piglets.并减轻仔猪产肠毒素性大肠杆菌诱导的肠道炎症,稳定肠道微生物群和血清代谢物。
Anim Nutr. 2025 Jun 20;22:165-178. doi: 10.1016/j.aninu.2025.04.005. eCollection 2025 Sep.
3
Fueling immunity: the synergy of natural products and exercise for optimal health.

本文引用的文献

1
A proteomic insight reveals the role of food-associated C9O4 in reverting intestinal inflammation.蛋白质组学研究揭示了食物相关的C9O4在逆转肠道炎症中的作用。
iScience. 2023 Nov 17;26(12):108481. doi: 10.1016/j.isci.2023.108481. eCollection 2023 Dec 15.
2
inhibits NF-κB/NLRP3/Caspase-1 signaling pathway to antagonize enterotoxigenic -mediated inflammatory response.抑制NF-κB/NLRP3/半胱天冬酶-1信号通路,以拮抗产肠毒素介导的炎症反应。
Can J Microbiol. 2024 Apr 1;70(4):109-118. doi: 10.1139/cjm-2023-0038. Epub 2023 Dec 22.
3
CNCM I-4866, a potential probiotic candidate, shows anti-inflammatory properties and .
增强免疫力:天然产物与运动协同作用促进最佳健康状态
Front Pharmacol. 2025 Jul 31;16:1582540. doi: 10.3389/fphar.2025.1582540. eCollection 2025.
4
The impact of probiotics on glycemic control during the first 3 months after sleeve gastrectomy: a prospective placebo‑controlled study.益生菌对袖状胃切除术后前3个月血糖控制的影响:一项前瞻性安慰剂对照研究。
Wideochir Inne Tech Maloinwazyjne. 2025 Jul 4;20(2):190-195. doi: 10.20452/wiitm.2025.17968. eCollection 2025 Jul 8.
5
Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review.胰高血糖素样肽1(GLP-1)在炎症性肠病中的相关性:一项叙述性综述
Curr Issues Mol Biol. 2025 May 21;47(5):383. doi: 10.3390/cimb47050383.
6
A Review of the Influence of Prebiotics, Probiotics, Synbiotics, and Postbiotics on the Human Gut Microbiome and Intestinal Integrity.益生元、益生菌、合生元和后生元对人体肠道微生物群和肠道完整性影响的综述
J Clin Med. 2025 May 23;14(11):3673. doi: 10.3390/jcm14113673.
7
Therapeutic Potential of Probiotics: A Review of Their Role in Modulating Inflammation.益生菌的治疗潜力:对其在调节炎症中作用的综述
Probiotics Antimicrob Proteins. 2025 Jun 4. doi: 10.1007/s12602-025-10609-z.
8
Gut microbiota, inflammatory cytokines, and Kawasaki disease: a Mendelian randomization study and mediation analysis.肠道微生物群、炎性细胞因子与川崎病:一项孟德尔随机化研究及中介分析
Pediatr Res. 2025 Feb 10. doi: 10.1038/s41390-025-03911-7.
9
The Microbiota-Gut-Brain Axis: Key Mechanisms Driving Glymphopathy and Cerebral Small Vessel Disease.微生物群-肠道-脑轴:驱动类淋巴系统病变和脑小血管疾病的关键机制
Life (Basel). 2024 Dec 24;15(1):3. doi: 10.3390/life15010003.
10
Efficacy of Probiotics in the Management of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.益生菌在肠易激综合征管理中的疗效:一项系统评价与荟萃分析。
Cureus. 2024 Dec 18;16(12):e75954. doi: 10.7759/cureus.75954. eCollection 2024 Dec.
CNCM I-4866是一种潜在的益生菌候选物,具有抗炎特性 以及 。(原文此处似乎不完整)
Front Microbiol. 2023 Nov 29;14:1270974. doi: 10.3389/fmicb.2023.1270974. eCollection 2023.
4
A Ropy Exopolysaccharide-Producing Strain Bi-OTA128 Alleviates Dextran Sulfate Sodium-Induced Colitis in Mice.一株产粘性胞外多糖的菌株 Bi-OTA128 可缓解葡聚糖硫酸钠诱导的小鼠结肠炎。
Nutrients. 2023 Dec 1;15(23):4993. doi: 10.3390/nu15234993.
5
Lactobacillus rhamnosus probiotic treatment modulates gut and liver inflammatory pathways in a hepatocellular carcinoma murine model. A preliminary study.鼠肝癌模型中,罗伊氏乳杆菌益生菌治疗可调节肠道和肝脏炎症途径。一项初步研究。
Food Chem Toxicol. 2024 Jan;183:114314. doi: 10.1016/j.fct.2023.114314. Epub 2023 Dec 3.
6
-derived indole-3-lactic acid ameliorates colitis in cesarean-born offspring via activation of aryl hydrocarbon receptor.源自吲哚-3-乳酸通过激活芳烃受体改善剖宫产出生子代的结肠炎。
iScience. 2023 Oct 19;26(11):108279. doi: 10.1016/j.isci.2023.108279. eCollection 2023 Nov 17.
7
Microbiota and IBD: Current knowledge and future perspectives.肠道微生物群与炎症性肠病:现有知识与未来展望。
Dig Liver Dis. 2024 Jun;56(6):911-922. doi: 10.1016/j.dld.2023.11.015. Epub 2023 Nov 25.
8
Gut Microbiome-Based Therapeutics in Critically Ill Adult Patients-A Narrative Review.基于肠道微生物组的成年危重症患者治疗方法:叙述性综述。
Nutrients. 2023 Nov 9;15(22):4734. doi: 10.3390/nu15224734.
9
Attenuates Cisplatin-Induced Intestinal Mucositis in Mice via Modulating the Gut Microbiota and Improving Intestinal Inflammation.通过调节肠道微生物群和改善肠道炎症减轻顺铂诱导的小鼠肠道粘膜炎
Pathogens. 2023 Nov 11;12(11):1340. doi: 10.3390/pathogens12111340.
10
Lactobacillus plantarum modulate gut microbiota and intestinal immunity in cyclophosphamide-treated mice model.植物乳杆菌调节环磷酰胺处理的小鼠模型中的肠道微生物群和肠道免疫。
Biomed Pharmacother. 2023 Dec 31;169:115812. doi: 10.1016/j.biopha.2023.115812. Epub 2023 Nov 16.